Pulmatrix, Inc. (PULM)
Nasdaq: PULM · Pharmaceutical Preparations · Framingham, MA · filing with the SEC since 2013
Income statement, as filed
In thousands of US dollars (USD), as filed; per-share figures in US dollars; share counts. The fiscal year ends in December.| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Period ending | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 | Dec 31, 2016 |
| Report filed | Feb 26, 2026 | Mar 21, 2025 | Mar 28, 2024 | Mar 30, 2023 | Mar 29, 2022 | Mar 23, 2021 | Mar 26, 2020 | Feb 19, 2019 | Mar 13, 2018 | Mar 10, 2017 |
| Revenue | · | 7,806 | 7,298 | 6,071 | 5,169 | 12,634 | 7,910 | 153 | 335 | 835 |
| For lenders | ||||||||||
| Net interest income | · | 467 | 867 | 309 | 7 | 82 | · | · | · | · |
| Research and development | 38 | 7,166 | 15,518 | 18,240 | 15,382 | 15,609 | 12,845 | 12,966 | 10,243 | 10,152 |
| General and administrative | 5,131 | 7,785 | 6,520 | 6,778 | 6,377 | 6,887 | 8,489 | 7,518 | 7,567 | 8,015 |
| Total operating expenses | 5,169 | 17,569 | 22,038 | 25,018 | 25,336 | 22,496 | 28,602 | 20,553r | 17,810 | 25,701 |
| Operating income | -5,169 | -9,763 | -14,740 | -18,947 | -20,167 | -9,862 | -20,692 | -20,400r | -17,475 | -24,866 |
| Interest expense | · | · | · | · | · | · | · | 186 | 643 | 881 |
| Interest and investment income | 144 | 467 | · | · | · | 82 | 301 | 27 | · | · |
| Other income (expense), net | -204 | -196 | -248 | -198 | -11 | -239 | -5 | -5r | 28 | -2 |
| Total non-operating income (expense) | 7 | 204 | 619 | 111 | -4 | -9,446 | 96 | -163r | -581 | · |
| Income before income taxes | · | · | · | · | · | · | · | · | -18,056 | -30,802 |
| Income tax expense | 0 | · | · | · | · | · | · | · | · | -2,959 |
| Net income including non-controlling interests | · | · | · | · | · | · | -20,596 | -20,563 | -18,056 | · |
| Net income | -5,162 | -9,559 | -14,121 | -18,836 | -20,171 | -19,308 | -20,596 | -20,563 | -18,056 | -27,843 |
| Net income to common shareholders | · | · | · | -18,836 | -23,368 | -19,308 | · | · | · | -27,843 |
| Earnings per share, basic | -1.41 | -2.62 | -3.87 | -5.46 | -8.63 | · | · | · | · | · |
| Earnings per share, diluted | -1.41 | -2.62 | -3.87 | -5.46 | · | · | · | · | · | · |
| Earnings per share, basic and diluted | · | · | · | · | -8.63 | -13.43r | -1.23 | -4.98 | -9.32r | -1.88 |
| Weighted average shares, basic | 3,652,285 | 3,652,285 | 3,651,911r | 3,447,701rb | 2,708,558 | · | · | · | · | · |
| Weighted average shares, diluted | 3,652,285 | 3,652,285 | 3,651,911r | 3,447,701,000 | · | · | · | · | · | · |
| Weighted average shares, basic and diluted | · | · | · | · | 2,708,558 | 1,437,666r | 16,733,909 | 4,126,393 | 1,937,161r | 14,815,230 |
As filed with the SEC, each figure from the newest report that carries it, and linked to it. Nothing here is computed.A dot is a line not tagged for that period. r restated by the company in a later report; b a share figure put on the newest basis or filed in the wrong unit. Hover a figure for its filing and note.
What each line is, and the XBRL concept behind it
Revenue what customers paid for what it sold
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
us-gaap:RevenuesNet interest income interest earned less interest paid
us-gaap:InterestIncomeExpenseNetResearch and development spent on inventing what it sells next
us-gaap:ResearchAndDevelopmentExpenseGeneral and administrative the cost of running the company itself
us-gaap:GeneralAndAdministrativeExpenseTotal operating expenses the running costs together
us-gaap:OperatingExpensesOperating income profit from running the business, before interest and tax
us-gaap:OperatingIncomeLossInterest expense what its borrowing cost
us-gaap:InterestExpenseInterest and investment income what its cash and investments earned
us-gaap:InvestmentIncomeInterestOther income (expense), net gains and costs outside the business
us-gaap:OtherNonoperatingIncomeExpenseTotal non-operating income (expense) everything outside the business, together
us-gaap:NonoperatingIncomeExpenseIncome before income taxes profit before tax
us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterestIncome tax expense tax charged on the period's profit
us-gaap:IncomeTaxExpenseBenefitNet income including non-controlling interests the whole group's profit, minority holders' share included
us-gaap:ProfitLossNet income the profit or loss that belongs to the company's shareholders
us-gaap:NetIncomeLossNet income to common shareholders what is left for common shareholders
us-gaap:NetIncomeLossAvailableToCommonStockholdersBasicEarnings per share, basic net income per share outstanding
us-gaap:EarningsPerShareBasicEarnings per share, diluted net income per share, counting every share that could be issued
us-gaap:EarningsPerShareDilutedEarnings per share, basic and diluted net income per share, where both counts are the same
us-gaap:EarningsPerShareBasicAndDilutedWeighted average shares, basic the average count of shares outstanding
us-gaap:WeightedAverageNumberOfSharesOutstandingBasicWeighted average shares, diluted the average count with every share that could be issued
us-gaap:WeightedAverageNumberOfDilutedSharesOutstandingWeighted average shares, basic and diluted the average count, where both counts are the same
us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted